
**What is claimed is:**

1. A pharmaceutical composition comprising Compound 1:




1,

or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent, wherein the carrier or diluent is mannitol, and wherein the amount of mannitol is from 80 to 98 % w/w.

2. The pharmaceutical composition of claim 1, further comprising a glidant, an acidifier, a lubricant, or a mixture thereof.

3. The pharmaceutical composition of claim 1, comprising: 1) Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, at an amount of from 0.05 to 3 % w/w; 2) mannitol at an amount of from 80 to 98 % w/w; 3) a glidant at an amount of from 0 to 10 % w/w; 4) an acidifier at an amount of from 0 to 6 % w/w; and 5) a lubricant at an amount of from 0 to 8 % w/w.

4. The pharmaceutical composition of claim 3, wherein Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, is free base of Compound 1.

5. The pharmaceutical composition of claim 4, wherein the free base of Compound 1 is a crystalline free base of Compound 1.

6. The pharmaceutical composition of claim 4, wherein the free base of Compound 1 is characterized by an XRPD pattern comprising peaks at 14.6, 18.2, and 18.3º 2θ ± 0.2 2θ.

7. The pharmaceutical composition of any one of claims 3 to 6, wherein the amount of Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, is from 0.1 to 1.5 % w/w.

8. The pharmaceutical composition of claim 7, wherein the amount of Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, is from 0.13 to 1 % w/w.

9. The pharmaceutical composition of any one of claims 3 to 8, wherein the amount of mannitol is from 85 to 95 % w/w.

10. The pharmaceutical composition of claim 9, wherein the amount of mannitol is from 90 to 93 % w/w.

11. The pharmaceutical composition of any one of claims 3 to 10, wherein the glidant is silica dimethyl silylate or colloidal silicon dioxide.

12. The pharmaceutical composition of any one of claims 3 to 11, wherein the amount of the glidant is from 0.25 to 3 % w/w.

13. The pharmaceutical composition of claim 12, wherein the amount of the glidant is from 0.5 to 2 % w/w.

14. The pharmaceutical composition of any one of claims 3 to 13, wherein the acidifier is fumaric acid.

15. The pharmaceutical composition of any one of claims 3 to 14, wherein the amount of the acidifier is from 2 to 5 % w/w.

16. The pharmaceutical composition of claim 15, wherein the amount of the acidifier is 3 % w/w.

17. The pharmaceutical composition of any one of claims 3 to 16, wherein the lubricant is stearic acid.

18. The pharmaceutical composition of any one of claims 3 to 17, wherein the amount of the lubricant is from 2 to 6 % w/w.

19. The pharmaceutical composition of claim 18, wherein the amount of the lubricant is 4 % w/w.

20. The pharmaceutical composition of claim 3, comprising: 1) Compound 1 at an amount of 0.13 % w/w; 2) mannitol at an amount of 92.37 % w/w; 3) silica dimethyl silylate at an amount of 0.5 % w/w; 4) fumaric acid at an amount of 3 % w/w; and 5) stearic acid at an amount of 4 % w/w.

21. The pharmaceutical composition of claim 20, having a total weight of 75 mg.

22. The pharmaceutical composition of claim 21, which is contained in a size 4 capsule.

23. The pharmaceutical composition of claim 3, comprising: 1) Compound 1 at an amount of 0.5 % w/w; 2) mannitol at an amount of 91.5 % w/w; 3) colloidal silicon dioxide at an amount of 1 % w/w; 4) fumaric acid at an amount of 3 % w/w; and 5) stearic acid at an amount of 4 % w/w.

24. The pharmaceutical composition of claim 23, having a total weight of 100 mg.


25. The pharmaceutical composition of claim 24, which is contained in a size 3 capsule.

26. The pharmaceutical composition of claim 3, comprising: 1) Compound 1 at an amount of 1 % w/w; 2) mannitol at an amount of 90 % w/w; 3) colloidal silicon dioxide at an amount of 2 % w/w; 4) fumaric acid at an amount of 3 % w/w; and 5) stearic acid at an amount of 4 % w/w.

27. The pharmaceutical composition of claim 26, having a total weight of 200 mg.

28. The pharmaceutical composition of claim 27, which is contained in a size 2 capsule.

29. A pharmaceutical composition comprising Compound 1:




Compound 1,

or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent, wherein the carrier or diluent is a mixture of starch and lactose.

30. The pharmaceutical composition of claim 29, further comprising a glidant, an acidifier, a lubricant, a disintegrant, or a mixture thereof.

31. The pharmaceutical composition of claim 29, comprising: 1) Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, at an amount of from 0.05 to 3 % w/w; 2) a mixture of starch and lactose at an amount of from 70 to 90 % w/w; 3) a glidant at an amount of from 0 to 10 % w/w; 4) an acidifier at an amount of from 0 to 8 % w/w; 5) a lubricant at an amount of from 0 to 8 % w/w; and 6) a disintegrant at an amount of from 0 to 20 % w/w.

32. The pharmaceutical composition of claim 31, wherein Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, is free base of Compound 1.

33. The pharmaceutical composition of claim 32, wherein the free base of Compound 1 is a crystalline free base of Compound 1.

34. The pharmaceutical composition of claim 32, wherein the free base of Compound 1 is characterized by an XRPD pattern comprising peaks at 14.6, 18.2, and 18.3º 2θ ± 0.2 2θ.

35. The pharmaceutical composition of any one of claims 31 to 34, wherein the amount of Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, is from 0.1 to 1.5 % w/w.

36. The pharmaceutical composition of claim 35, wherein the amount of Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, is from 0.13 to 1 % w/w.

37. The pharmaceutical composition of any one of claims 31 to 36, wherein the starch is partially pregelatinized starch.

38. The pharmaceutical composition of any one of claims 31 to 37, wherein the lactose is anhydrous lactose.

39. The pharmaceutical composition of any one of claims 31 to 38, wherein the amount of the starch is from 17 to 22 % w/w, and the amount of the lactose is from 53 to 68 % w/w.

40. The pharmaceutical composition of any one of claims 31 to 38, wherein the amount of the mixture of starch and lactose is from 75 to 85 % w/w.

41. The pharmaceutical composition of claim 40, wherein the amount of the starch is from 18 to 21 % w/w, and the amount of the lactose is from 57 to 64 % w/w.

42. The pharmaceutical composition of any one of claims 31 to 38, wherein the amount of the mixture of starch and lactose is from 80 to 82 % w/w.

43. The pharmaceutical composition of claim 42, wherein the amount of the starch is from 19 to 20 % w/w, and the amount of the lactose is from 61 to 62 % w/w.

44. The pharmaceutical composition of any one of claims 31 to 38, wherein the weight ratio of the starch to the lactose is from 1:2 to 1:4.

45. The pharmaceutical composition of claim 44, wherein the weight ratio of the starch to the lactose is from 1:3 to 1:3.3.

46. The pharmaceutical composition of any one of claims 31 to 45, wherein the glidant is silica dimethyl silylate or colloidal silicon dioxide.

47. The pharmaceutical composition of any one of claims 31 to 46, wherein the amount of the glidant is from 0.25 to 3 % w/w.

48. The pharmaceutical composition of claim 47, wherein the amount of the glidant is from 0.5 to 1 % w/w.

49. The pharmaceutical composition of any one of claims 31 to 48, wherein the acidifier is fumaric acid.

50. The pharmaceutical composition of any one of claims 31 to 49, wherein the amount of the acidifier is from 2 to 6 % w/w.

51. The pharmaceutical composition of claim 50, wherein the amount of the acidifier is 4 % w/w.

52. The pharmaceutical composition of any one of claims 31 to 51, wherein the lubricant is stearic acid.

53. The pharmaceutical composition of any one of claims 31 to 52, wherein the amount of the lubricant is from 2 to 6 % w/w.

54. The pharmaceutical composition of claim 53, wherein the amount of the lubricant is 4 % w/w.

55. The pharmaceutical composition of any one of claims 31 to 54, wherein the disintegrant is sodium starch glycolate.

56. The pharmaceutical composition of claim 55, wherein the amount of the disintegrant is from 5 to 15 % w/w.

57. The pharmaceutical composition of claim 56, wherein the amount of the disintegrant is 10 % w/w.

58. The pharmaceutical composition of claim 31, comprising: 1) Compound 1 at an amount of 0.13 % w/w; 2) partially pregelatinized starch at an amount of 20 % w/w and anhydrous lactose at an amount of 61.4 % w/w; 3) silica dimethyl silylate at an amount of 0.5 % w/w; 4) fumaric acid at an amount of 4 % w/w; 5) stearic acid at an amount of 4 % w/w; and 6) sodium starch glycolate at an amount of 10 % w/w.

59. The pharmaceutical composition of claim 58, having a total weight of 75 mg.

60. The pharmaceutical composition of claim 59, which is contained in a size 4 capsule.

61. The pharmaceutical composition of claim 31, comprising: 1) Compound 1 at an amount of 0.5 % w/w; 2) partially pregelatinized starch at an amount of 19.5 % w/w and anhydrous lactose at an amount of 61 % w/w; 3) colloidal silicon dioxide at an amount of 1 % w/w; 4) fumaric acid at an amount of 4 % w/w; 5) stearic acid at an amount of 4 % w/w; and 6) sodium starch glycolate at an amount of 10 % w/w.

62. The pharmaceutical composition of claim 61, having a total weight of 100 mg.

63. The pharmaceutical composition of claim 62, which is contained in a size 3 capsule.

64. The pharmaceutical composition of claim 31, comprising: 1) Compound 1 at an amount of 1 % w/w; 2) partially pregelatinized starch at an amount of 19 % w/w and anhydrous lactose at an amount of 61 % w/w; 3) colloidal silicon dioxide at an amount of 1 % w/w; 4) fumaric acid at an amount of 4 % w/w; 5) stearic acid at an amount of 4 % w/w; and 6) sodium starch glycolate at an amount of 10 % w/w.

65. The pharmaceutical composition of claim 64, having a total weight of 200 mg.

66. The pharmaceutical composition of claim 65, which is contained in a size 2 capsule.

67. Use of a pharmaceutical composition of any one of claims 1-66 in the manufacture of a medicament for a method of treating multiple myeloma in a patient.

68. A process for preparing a pharmaceutical composition of any one of claims 1 to 66, comprising coating Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, with a hydrophobic silica.

69. The process of claim 68, wherein the coating is conducted by blending Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and the hydrophobic silica to form a binary blend, before blending with additional excipients.

70. The process of claim 68 or 69, wherein the hydrophobic silica is silica dimethyl silylate.